Obsidian 10-Q: $50.7M Q3 Loss, $324.4M Cash Into 2H 2028, New Director
OBX sits 30% above its 52-week low of $9.6.
Summary
Obsidian's first post-merger 10-Q shows a $50.7 million Q3 loss (including a $15.1 million Galera IPR&D charge) and $324.4 million in cash and securities, enough to fund operations into the second half of 2028. The filing also adds a new independent director and extended Bedford and Cambridge leases.
Key Events · Earnings and Guidance · OBX
-
Q3 Loss of $50.7M on Galera Charge
Net loss was $50.7 million, or $1.23 per share, for the three months ended September 30, 2026, including $15.1 million of acquired in-process R&D expense tied to the Galera transaction.
-
Cash of $324.4M Funds Operations Into 2H 2028
Cash, cash equivalents and marketable securities totaled $324.4 million at September 30, 2026, up from $80.5 million at year-end 2025 after the $350.0 million PIPE, which the company expects to support operations into the second half of 2028.
-
New Independent Director Added
The board expanded from six to seven directors with the November 10, 2026 appointment of Mark Reisenauer, former Assertio CEO; he received an initial option for 75,364 shares at $13.74.
-
Bedford and Cambridge Leases Extended
The Bedford lease was extended through May 31, 2031 with 16,091 additional square feet, and the Cambridge lease through May 31, 2027, adding roughly $1.1 million to the operating lease liability and right-of-use asset.
Analysis · OBX · Life Sciences
The 10-Q confirms the quarter the 8-K flagged hours earlier, but it is the first full look at the post-merger balance sheet: $324.4 million in cash and securities against a $50.7 million quarterly loss, with the company guiding that runway into the second half of 2028. A one-time $15.1 million charge for the Galera in-process R&D inflates the loss, so the underlying cash burn is closer to $35 million a quarter. Two new items land here rather than in the 8-K: a seventh board seat filled by commercial oncology executive Mark Reisenauer, and lease amendments that lock in the Bedford expansion through 2031 and the Cambridge space through May 2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OBX was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.9M. The 52-week trading range was $9.60 to $49.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.